<DOC>
	<DOCNO>NCT02979522</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , anti-tumor activity , well recommend dose brentuximab vedotin ( ADCETRIS ) combination multiagent chemotherapy regimen , doxorubicin ( Adriamycin ) , vinblastine , dacarbazine , pediatric participant advance stage newly diagnose Hodgkin Lymphoma ( HL ) .</brief_summary>
	<brief_title>A Study Brentuximab Vedotin + Adriamycin , Vinblastine , Dacarbazine Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma</brief_title>
	<detailed_description>The drug test study call brentuximab vedotin . Brentuximab vedotin test treat pediatric participant advanced stage , newly diagnose , classical CD30+ HL . This study ass safety , tolerability , anti-tumor activity , well recommend dose brentuximab vedotin combination multiagent chemotherapy regimen base current standard care ( SOC ) first-line treatment regimen newly diagnose HL . The study enroll approximately 55 evaluable participant . The study conduct 2 phase , Phase 1 Phase 2 . Phase 1 study enroll 12 participant determine recommend dose . Once recommend dose identify additional participant enrol phase 2 total number evaluable participant approximately 55 , include participant treat recommend dose Phase 1 . Participants enrol follow 2 dose Cohorts : â€¢ Brentuximab vedotin 48 mg/m^2 36 mg/m^2 combination doxorubicin , vinblastine , dacarbazine . This multi-center trial conduct United States ( US ) Europe . The overall time participate study approximately 55 month . Participants follow maximum 30 day follow last dose protocol therapy follow-up assessment follow survival death study closure maximum 2 year enrollment last participant .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Each participant must meet follow inclusion criterion enrol study : 1 . Histologically confirm CD30+ classical HL . 2 . Advanced stage , newly diagnose HL ( Stage III Stage IV disease ) . 3 . Treatmentnaive HL . 4 . Have performance score great equal ( &gt; = ) 50 Lansky Playperformance Karnofsky Performance Status . 1 . Nodular lymphocyte predominant HL . 2 . Known active cerebral/meningeal disease , include sign symptom progressive multifocal leukoencephalopathy ( PML ) history PML . 3 . Any sensory motor peripheral neuropathy . 4 . Symptomatic neurologic disease compromise normal activity daily live require medication .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug therapy , pediatric Hodgkin disease , frontline Hodgkin disease , advanced stage Hodgkin disease , pediatric lymphoma</keyword>
</DOC>